SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
1. Faruqi & Faruqi is investigating claims against Rocket Pharmaceuticals. 2. Investors suffered losses over $50,000 between February and May 2025. 3. FDA placed a clinical hold on RP-A501 after severe adverse events. 4. Rocket's stock price fell 37% after the FDA announcement. 5. Class action deadline for lead plaintiff role is August 11, 2025.